What is NSCLC Phase I PBF-509 AdenONCO Study?

Category: Others

false

NCT02403193 is a phase 1 dose escalation trial assessing the safety and feasibility of PBF-509 in patients with non-small cell lung cancer (NSCLC).

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 0
Moderate 0
Mild 5
None 2

Commonly reported side effects and conditions associated with NSCLC Phase I PBF-509 AdenONCO Study

Side effect Patients
Fatigue 1
Rash on torso 1

Dosages

Based on patients currently using NSCLC Phase I PBF-509 AdenONCO Study

Dosage Patients
80 mg twice daily 1

Duration

Currently using NSCLC Phase I PBF-509 AdenONCO Study

Duration Patients
1 - 6 months 1
Adherence
Adherence Evaluations
Always 7
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 5
A little hard to take 2
Not at all hard to take 0
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 7
Not specified 0
Last updated:
There are no evaluations for NSCLC Phase I PBF-509 AdenONCO Study.